Business Context and Reporting Period
This Form 8-K is a current report filed by Seneca Biopharma, Inc. (trading symbol: SNCA) on December 20, 2019. The filing serves to update the Company's beneficial ownership disclosure regarding its non-affiliate float. As of the report date, the Company had 3,866,457 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity ownership structure rather than financial performance.
Material Changes and Ownership Structure
The report details the beneficial ownership of the Company's capital stock as of December 20, 2019. Key ownership statistics include:
- 5% Owners: Tianjin Pharmaceuticals Group International Holdings Co., LTD holds 303,984 shares (7.78% of the class), including shares underlying convertible securities.
- Directors and Officers: All current directors and named executive officers (13 individuals) collectively hold 189,988 shares (4.71% of the class).
- Combined Group: The aggregate holding of directors, officers, and 5% owners is 493,972 shares (12.45% of the class).
Several footnotes indicate recent leadership changes, including the resignation of former CEO Richard Daly (July 2018), former CEO James Scully (December 2018), and various directors in 2019.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. The document is a routine disclosure of stock ownership percentages.
Investor Verification Checklist
- Verify the total number of shares outstanding (3,866,457) against recent 10-K or 10-Q filings to confirm the non-affiliate float calculation.
- Review the status of convertible securities held by directors and officers to understand potential dilution within the 60-day window.
- Confirm the current status of the 5% holder, Tianjin Pharmaceuticals Group, to assess potential influence on corporate governance.
- Check subsequent filings for updates on the leadership team, as several individuals listed have resigned or had terms expire prior to the report date.